Recombinant human erythropoietin in the treatment of chemotherapy- induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

Annals of Oncology

Volumn 9, Issue 3, 1998, Pages 255-260

  Oberhoff, C ^a   Neri, B ^b   Amadori, D ^c   Petry, K U ^d   Gamucci, T ^e   Rebmann, U ^f   Nowrousian, M R ^a   Voigtmann, R ^g   Monfardini, S ^h   Armand, J P ⁱ   Herrmann, R ^j   Netter Pinon, J ^k   Tubiana Mathieu, N ^l   Zwierzina, H ^m  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Policlin D   (Italy)

^c Ospedale Pierantoni   (Italy)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f Krankenhaus Diakonieanstalten   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k Clinique Courlancy   (France)

^l DUPUYTREN UNIVERSITY HOSPITAL   (France)

^m INNSBRUCK MEDICAL UNIVERSITY   (Austria)

more..

Author keywords

Anemia; Chemotherapy; Malignancy; Recombinant human erythropoietin

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 7144223394     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008296622469     Document Type: Article

References (23)

1. Nowrousian MR, Essers U, Voigtmann R et al. Pathophysiology of cancer- related anemia. In Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker, Inc 1996; 13-34.
2. Facquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79; 1987-94.
3. von Hoff DD, Schilsky R, Reichert CM et al. Toxic effects of cisdichlorodiammineplatinum (II) in man. Cancer Treat Rep 1979; 63: 1527-31.
4. Miller CB. Chemotherapy-induced anemia. In Gurland HJ, Moran J, Samtleben W, Scigalla P, Wieczorek L (eds): Erythropoietin in Renal und Non-Renal Anemias. Basel: Karger, Contrib Nephrol 1991; 88: 248-51.
5. Wood PA, Hrushesky JM. Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest 1995; 95: 1650-9.
6. ten Bokkel-Huinink WW. Controlled multicenter study of the influence of two different dosages of subcutaneous rhEPO on the development of anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based combination chemotherapy. In Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker, Inc 1996; 99-112.
7. Walker RH. Special report: Transfusion risks. Am J Clin Pathol 1987; 88: 375-8.
8. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 11: 1175-8.
9. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin; Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
10. Ludwig H, Fritz E, Leitgeb C et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4: 161-7.
11. Miller CB, Platanias LC, Mills SR et al. Phase I II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992; 84: 98-103.
12. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995; 86: 4446-53.
13. Barosi G, Cazzola M, De Vincentiis A et al. Guidelines for the use of recombinant erythropoietin. Haematologica 1994; 79: 526-33.
14. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994; 84: 997-1004.
15. Beguin Y, Yerna M, Loo M et al. Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992; 82: 648-53.
16. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A (Suppl 2): S2-S8.
17. Drüecke TB, Barany P, Cazzola et al. Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol (in press).
18. Cazzola M, Ponchio L, Beguin Y et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I-II clinical trial. Blood 1992; 79: 29-37.
19. Ponchio L, Beguin Y, Farina G et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anemia. Haematologica 1992; 77: 494-501.
20. Österborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma a randomized multicenter study. Blood 1996; 87: 2675-82.
21. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992; 87: 4-11.
22. Piroso E, Erslev A, Caro J. Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol 1989; 32: 248-254.
23. Barosi G, Liberato NL. The cost-effectiveness of rhEPO use in anemia of cancer. In Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker, Inc 1996; 45-57.